Publikationen – Universitäts-Hautklinik Tübingen
Universitäts-Hautklinik Tübingen

Eine aktuelle Literaturliste der Mitarbeiter der Hautklinik Tübingen finden Sie in der Literatur-Datenbank PubMed.
Ascierto PA, Del Vecchio  M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M (2017) Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. Mar 27. pii: S1470-2045(17)30231-0. doi: 10.1016/S1470-2045(17)30231-0.

Dummer  R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K (2017) Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. Mar 8. pii: S1470-2045(17)30180-8. doi: 10.1016/S1470-2045(17)30180-8. [Epub ahead of print]

Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K (2017) An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:528-537.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. (2016)  Cobimetinib  combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630-40.

Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte K-W, Lehmann P, Vogt T, Ulrich J ,Herbst R, Gehring W, Simon J-C, Keim U, Martus P, Garbe C (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 17:757-767.

Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T (2016) Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentr, single-arm, open-label, phase 2a, proof-of-concept trial. The Lancet, Haematology 3: e72–e79.

Zipperer A, Konnerth MC, Laux C, Berscheid A, Janek D, Weidenmaier C, Burian M, Schilling NA, Slavetinsky C, Marschal M, Willmann M, Kalbacher H, Schittek B, Brötz-Oesterhelt H, Grond S, Peschel A, Krismer B (2016) Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535:511-6.

Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G, Ehrlichmann W, Bukala D, Harant M, Cay F, Brück J, Nordin R, Kohlhofer U, Rammensee HG, Quintanilla-Martinez L, Schaller M, Röcken M, Pichler BJ, Kneilling M (2015) 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A 112:1161-1166.

Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Köberle M, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark RA, Röcken M, Biedermann T (2015) IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA 112:2163-2168.

Hauschild A, Garbe C (2015) Immunotherapy: Combined immunotherapy–a new standard in metastatic melanoma? Nat Rev Clin Oncol 12: 439-440.

Long, G. V, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. J. Grob, V. Chiarion-Sileni, C. Lebbe, M. Mandalà, M. Millward, A. Arance, I. Bondarenko, J. B. Haanen, J. Hansson, J. Utikal, V. Ferraresi, N. Kovalenko, P. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, D. J. DeMarini, J. G. Irani, S. Swann, J. J. Legos, F. Jin, B. Mookerjee and K. Flaherty (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386: 444-451.

Lorigan, P, P. A. Ascierto, R. Dummer, A. M. Eggermont, K. T. Flaherty, C. Garbe, H. Gogas, A. Hauschild, R. F. Kefford, J. M. Kirkwood, J. Larkin, G. V. Long, M. Maio, G. A. McArthur, A. Ribas, C. Robert, D. Schadendorf, V. K. Sondak, J. D. Wolchok and A. M. Hudson (2015) Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol 16:15-17.

Maio, M, J. J. Grob, S. Aamdal, I. Bondarenko, C. Robert, L. Thomas, C. Garbe, V. Chiarion-Sileni, A. Testori, T. T. Chen, M. Tschaika and J. D. Wolchok (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33:1191-1196.

Ribas, A, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F. S. Hodi, J. Schachter, A. C. Pavlick, K. D. Lewis, L. D. Cranmer, C. U. Blank, S. J. O’Day, P. A. Ascierto, A. K. Salama, K. A. Margolin, C. Loquai, T. K. Eigentler, T. C. Gangadhar, M. S. Carlino, S. S. Agarwala, S. J. Moschos, J. A. Sosman, S. M. Goldinger, R. Shapira-Frommer, R. Gonzalez, J. M. Kirkwood, J. D. Wolchok, A. Eggermont, X. N. Li, W. Zhou, A. M. Zernhelt, J. Lis, S. Ebbinghaus, S. P. Kang and A. Daud (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908-918.

Romano, E, M. Kusio-Kobialka, P. G. Foukas, P. Baumgaertner, C. Meyer, P. Ballabeni, O. Michielin, B. Weide, P. Romero and D. E. Speiser (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112: 6140-6145.

Van Allen, EM; Miao, D; Schilling, B; Shukla, SA; Blank, C; Zimmer, L; Sucker, A; Hillen, U; Geukes Foppen, MH; Goldinger, SM; Utikal, J; Hassel, JC; Weide, B; Kaehler, KC; Loquai, C; Mohr, P; Gutzmer, R; Dummer, R; Gabriel, S; Wu, CJ; Schadendorf, D; Garraway, LA (2015) Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 350:207-11.

De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Röcken M, Lütjohann D, Wright SD, Schultze JL, Latz E (2014) High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 15:152-160.

Larkin J, Ascierto P A, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak M A, Chang I, Choong N, Hack S P, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867-1876

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller W H, Mandalà M, Hospers G A, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU (2014) Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15: 436-444.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877-1888.

McArthur, G. A, P. B. Chapman, C. Robert, J. Larkin, J. B. Haanen, R. Dummer, A. Ribas, D. Hogg, O. Hamid, P. A. Ascierto, C. Garbe, A. Testori, M. Maio, P. Lorigan, C. Lebbé, T. Jouary, D. Schadendorf, S. J. O’Day, J. M. Kirkwood, A. M. Eggermont, B. Dréno, J. A. Sosman, K. T. Flaherty, M. Yin, I. Caro, S. Cheng, K. Trunzer and A. Hauschild (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-332.

Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Volz T, Rammensee HG, Schaller M, Röcken M, Götz F, Biedermann T (2014) Cutaneous innate immune sensing of toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 41:762-775.

Ulmer A, Dietz K, Hodak I, Polzer B, Scheitler S, Yildiz M, Czyz Z, Lehnert P, Fehm T, Hafner C, Schanz S, Röcken M, Garbe C, Breuninger H, Fierlbeck G, Klein CA (2014) Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 11:e1001604.

Van Allen, EM; Wagle, N; Sucker, A; Treacy, DJ; Johannessen, CM; Goetz, EM; Place, CS; Taylor-Weiner, A; Whittaker, S; Kryukov, GV; Hodis, E; Rosenberg, M; McKenna, A; Cibulskis, K; Farlow, D; Zimmer, L; Hillen, U; Gutzmer, R; Goldinger, SM; Ugurel, S; Gogas, HJ; Egberts, F; Berking, C; Trefzer, U; Loquai, C; Weide, B; Hassel, JC; Gabriel, SB; Carter, SL; Getz, G; Garraway, LA; Schadendorf, D and D. C. O. G. o. G. (DeCOG) (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discoveries 4:94-109.

Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F (2013) Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Science Signaling 6(260):ra7.

Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494:361-365.

O’Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A (2013) Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol 31:1211-1218.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, C, Garbe Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M,. McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616-622.

Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS (2012) Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A 109:18384-9.

EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bouna-meaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14), 1287-1297.

Flaherty, K. T, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L. V. Demidov, J. C. Hassel, P. Rutkowski, P. Mohr, R. Dummer, U. Trefzer, J. M. Larkin, J. Utikal, B. Dreno, M. Nyakas, M. R. Middleton, J. C. Becker, M. Casey, L. J. Sherman, F. S. Wu, D. Ouellet, A. M. Martin, K. Patel, D. Schadendorf M. S (2012) Group Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114.

Garbe, C (2012) Ipilimumab with fotemustine in metastatic melanoma. Lancet Oncol 13: 851-852.

Gross O*, Yazdi AS*, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J (2012) *equal contributions Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36:388-400.

Hirahara K, Ghoreschi K, Yang XP, Takahashi H, Laurence A, Vahedi G, Sciumè G, Hall AO, Dupont CD, Francisco LM, Chen Q, Tanaka M, Kanno Y, Sun HW, Sharpe AH, Hunter CA, O’Shea JJ (2012) Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 36:1017-30.

Hötzenecker W, Echtenacher B, Guenvoa E, Hötzenecker K, Wölbing F, Brück J, Teske A, Valtcheva N, Fuchs K, Kneilling M, Park JH, Kim KH, Kim KW, Hoffmann P, Krenn C, Hai T, Ghoreschi K, Biedermann T, Röcken M (2012) ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat Med 18(1), 128-34.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254-61.

Weide, B*; Zelba, H*; Derhovanessian, E; Pflugfelder, A; Eigentler, TK; Di Giacomo, AM; Maio, M; Aarntzen, EHJG; de Vries, IJM; Sucker, A; Schadendorf, D; Buttner, P; Garbe, C; Pawelec, G (2012) *: geteilte Erstautorschaft Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. Journal of Clinical Oncology 30:1835-41.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med.

Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M (2011) Fumarates improve pso-riasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11), 2291-2303.

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon JP, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med 364:2517-2526.

Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, Buchner J, Schaller M, Stange EF, Wehkamp J (2011) Reduction of disulfide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 469, 419-423.

EINSTEIN investigators, Bauersachs R et al. (2010) Oral rivaroxaban for symptomatic ve-nous thromboembolism. N Engl J Med 363(26), 2499-510.

Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C (2010) Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 28(5), 841-6.

Kamenisch Y, Fousteri M, Knoch J, von Thaler AK, Fehrenbacher B, Kato H, Becker T, Dollé ME, Kuiper R, Majora M, Schaller M, van der Horst GT, van Steeg H, Röcken M, Rapaport D, Krutmann J, Mullenders LH, Berneburg M (2010) Proteins of nucleotide and base excision repair pathways interact in mitochondria to protect from loss of subcutane-ous fat, a hallmark of aging. J Exp Med 207(2), 379-90.

Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F; Thymosin Melanoma Investigation Group (2010) Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 28(5), 841-6.

Röcken M (2010) Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 120,1800-3.

Spreu J, Kuttruff S, Stejfova V, Dennehy KM, Schittek B, Steinle A (2010) Interaction of C-type lectin-like receptors NKp65 and KACL facilitates dedicated immune recognition of human keratinocytes. Proc Natl Acad Sci U S A 107:5100-5105.

Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C (2009) Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol 28(10), 1780-7.

Kneilling M, Mailhammer R, Hültner L, Schönberger T, Fuchs K, Schaller M, Bukala D, Massberg S, Sander CA, Braumüller H, Eichner M, Maier KL, Hallmann R, Pichler BJ, Haubner R, Gawaz M, Pfeffer K, Biedermann T, Röcken M (2009) Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood 114(8), 1696-706.

Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi. Nature 457:599-602

Ziegler A, Heidenreich R, Braumuller H, Wolburg H, Weidemann S, Mocikat R, Rocken M (2009) EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009 Apr 9; 113(15), 3494-502.

Brantsch K, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, Breuninger H (2008) Prospective analysis of the risk factors determining prognosis of cutaneous squamous cell carcinoma. Lancet Oncology 9, 713-20.

Ghoreschi K, Thomas P, Penovici M, Ullmann J, Sander CA, Ledderose G, Plewig G, Kolb HJ, Röcken M (2008) PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol 18(6), 667-70.

Gremmel T, Wild S, Schuller W, Kürten V, Dietz K, Krutmann J, Berneburg M (2008) Six genes associated with the clinical phenotypes of individuals with deficient and proficient DNA repair. Transl Oncogen 3, 1-13.

Hartmann H, Eltzschig HK, Wurz H, Hantke K, Rakin A, Yazdi AS, Matteoli G, Bohn E, Autenrieth IB, Karhausen J, Neumann D, Colgan SP, Kempf VA (2008) Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores. Gastroenterology 134:756-67.

Judenhofer MS, Wehrl HF, Newprot DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy M, Eichner M, Klingel K, Reischl G, Widmaier S, Röcken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ (2008) Simultaneous PET/MRI: a new approach for functional and morphological imaging Nature Med 14,  459-65.

Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Förster I, Huss R, Weber WA, Kneilling M, Röcken M (2008) TNFR1- and IFN-y-signaling determine whether T cells induce tumor dormancy or promote multistage carcino genesis. Cancer Cell 13(6), 507-518.

Ulmer A, Beutel J, Süsskind D, Hilgers RD, Ziemssen F, Lüke M, Röcken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt KU, Grisanti S (2008) Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma. Clin Cancer Res 14(14),  4469-4474.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5: e120.

Bodo E, Tobin DJ, Kamenisch Y, Biro T, Berneburg M, Funk W, Paus R (2007) Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. Am J Pathol 171, 1153-1167.

Kneilling M, Hültner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V, Weber WA, Illges H, Haubner R, Röcken M (2007) Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 56(6), 1806-16.

Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F (2007) Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med. 13, 164-170.

Rebholz B, Haase I, Eckelt B, Paxian S, Flaig MJ, Ghoreschi K, Nedospasov SA, Mailhammer R, Debey-Pascher S, Schultze JL, Weindl G, Forster I, Huss R, Stratis A, Ruzicka T, Rocken M, Pfeffer K, Schmid RM, Rupec RA (2007) Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity (27), 296-307.

Weindl G, Naglik JR, Kaesler S, Biedermann T, Hube B, Korting, HC, Schaller M (2007) Epithelial cells establish direct antifungal defense through Toll-like receptor 4-mediated signaling. J Clin Invest 12, 3664-3672.

Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313(5786), 521-522.

Schaller M, Zakikhany K, Naglik JR, Weindl G, Hube B (2006) Models of oral and vaginal candidiasis based on in vitro reconstituted human epithelia. Nat Protoc 1, 2767-2773.

Schanz S, Ulmer A (2006) Medical mystery: gangrene and cutaneous nodules. N Engl J Med. 354(22), 2393-2394.

Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M (2005) The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10, 2986-3001. Review.

Schanz S, Schaefer J, Fierlbeck G (2005) Glucagonoma presenting with necrolytic migratory erythema: the Glucagonoma syndrome. Gastroenterology. 6, 1816, 2131.

Eigentler TK, Buettner PG, Leiter U, Garbe C (2004) Central Malignant Melanoma Registry of the German Dermatological Society.   Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol 21, 4376-4383.

Herzinger T, Plewig G, Röcken M (2004) Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 50(9):3045-6.

Leiter U, Buettner PG, Eigentler TK, Garbe C (2004) Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. J Clin Oncol 18, 3660-3667.

Schanz S, Fierlbeck G (2004) Images in clinical medicine. Scleromyxedema. N Engl J Med. 21, 2218.

Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M (2003) Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9, 40-46.

Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmuller G, Koszinowski U, Rocken M (2003) Natural killer cells activated by MHC class Ilow targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561-569.

Herzinger T, Schorling S, Röcken J, Röcken M (2002) A hoarse voice. Lancet 359(9314), 1308.

Röcken M, Hultner L (2002) Heavy functions for light chains. Nat Med 8, 668-670.

Schwarz A, Stander S, Berneburg M, Bohm M, Kulms D, van Steeg H, Grosse-Heitmeyer K, Krutmann J, Schwarz T (2002) Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 4, 26-31.

Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmüller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Röcken M (2001) Interleukin 4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2, 1054-1060.

Broughton BC, Berneburg M, Fawcett H, Taylor EM, Arlett CF, Nardo T, Stefanini M, Menefee E, Price VH, Queille S, Sarasin A, Bohnert E, Krutmann J, Davidson R, Kraemer KH, Lehmann AR (2001) Two individuals with features of both xeroderma pigmentosum and trichothiodystrophy highlight the complexity of the clinical outcomes of mutations in the XPD gene. Hum Mol Genet 2001 (10), 2539-2547.

Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, Schirle M, Schroeder K, Blin N, Meier F, Rassner G, Garbe C (2001) Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol. 12, 1133-1137.

Berneburg M, Clingen P, Harcourt, SA, Lowe JE, Taylor EM, Green MHL, Krutmann J, Arlett CF, Lehmann AR (2000) The Cancer-free Phenotype in Trichothiodystrophy is Unrelated to its Repair Defect. Cancer Res 60, 431-438.

Berneburg M, Lowe JE, Nardo T, Araujo, Fousteri MI, Green M, Krutmann J, Wood RD, Stefanini M, Lehmann AR (2000) UV damage causes uncontrolled DNA breakage in cells from patients with combined features of XP-D and Cockayne Syndrome. EMBO J 19 (5), 1157-1166.

Biedermann T, Kneilling M, Mailhammer R, Meier K, Sander CA, Kollias G, Kunkel S, Hültner L, Röcken M (2000) Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192, 1441-1452.

Egeter O, Mocikat R, Ghoreshi K, Dieckmann A, Röcken M (2000) Eradication of disseminated  lymphoma with CpG DNA activated T cells from non-transgenic mice. Cancer Res 60, 1515-1520.

Rohrmus B, Thoma-Greber EM, Bogner JR, Röcken M (2000) Outlook in oral and cutaneous Kaposi’s Sarcoma. Lancet 356, 2160.

Lüftl M, Degitz K, Plewig G, Röcken M (1997) Psoralen bath plus UV-A therapy. Possibilities and limitations. Arch Dermatol 133(12), 1597-603.

Kerscher M, Volkenandt M, Meurer M, Lehmann P, Plewig G, Rocken M (1994) Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 343, 1233 (letter).

Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, Shevach EM, Röcken M (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180(5), 1961-6.

Röcken M, Urban J, Shevach EM (1994) Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J Exp Med 179(6), 1885-93.

Röcken M, Müller KM, Saurat JH, Müller I, Louis JA, Cerottini JC, Hauser C (1992) Central role for TCR/CD3 ligation in the differentiation of CD4+T cells toward A Th1 or Th2 func-tional phenotype. J Immunol 148(1), 47-54.

Röcken M, Saurat JH, Hauser C (1992) A common precursor for CD4+ T cells producing IL-2 or IL-4. J Immunol 148(4), 1031-6.

Röcken M, Urban JF, Shevach EM (1992) Infection breaks T-cell tolerance. Nature 359, 79-82.

Vollenweider S, Saurat JH, Röcken M, Hauser C (1991) Evidence suggesting involvement of interleukin-4 (IL-4) production in spontaneous in vitro IgE synthesis in patients with atopic dermatitis. J Allgergy Clin Immunol 87(6), 1088-95.

nach oben